Literature DB >> 9769782

Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section.

H Tsuda1, F Akiyama, M Kurosumi, G Sakamoto, T Watanabe.   

Abstract

BACKGROUND: A multi-institutional randomized clinical trial of adjuvant therapy for patients with high-risk node-negative (n0) breast cancer has been undertaken in Japan. The pathology panel was organized in order to establish histological criteria to identify patient groups with higher rates of recurrence.
METHODS: Initially, three pathologists independently judged the nuclear grade, composed of nuclear atypia and mitotic counts, of 100 n0 invasive ductal carcinomas, focusing on interobserver variation of the nuclear grade and its correlation with patient prognosis. These pathologists then gave consensus histological types and nuclear grades for 130 other n0 breast carcinomas and examined the prognostic significance of the grade.
RESULTS: In the first study, nuclear grade 2-3 significantly identified a patient group with a rate of recurrence of 17-20% by any pathologists and the degree of agreement for the grade was fair. In the second study, the consensus type and nuclear grade identified a group (n = 66) with a 22% recurrence rate and another group (n = 64) with a 3.6% recurrence rate at 10 years. In 12 tumors, the resection-fixation interval of the tumor did not generate any significant difference in mitotic counts.
CONCLUSIONS: The histological type and the nuclear grade clearly identified a higher-risk patient group with n0 breast carcinoma, and may be applied to the multi-institutional protocol study when the criteria have been well standardized by the pathologists.

Entities:  

Mesh:

Year:  1998        PMID: 9769782     DOI: 10.1093/jjco/28.8.486

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  27 in total

1.  Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy.

Authors:  Tomoya Nagao; Takayuki Kinoshita; Nobuko Tamura; Takashi Hojo; Madoka Morota; Yoshikazu Kagami
Journal:  Int J Clin Oncol       Date:  2011-11-09       Impact factor: 3.402

2.  Cytoplasmic expression of the JM403 antigen GlcA-GlcNH3+ on heparan sulfate glycosaminoglycan in mammary carcinomas--a novel proliferative biomarker for breast cancers with high malignancy.

Authors:  Masahiro Fujii; Akiko Yusa; Yukihiro Yokoyama; Toshio Kokuryo; Nobuyuki Tsunoda; Koji Oda; Masato Nagino; Tsuyoshi Ishimaru; Yoshie Shimoyama; Hirotoshi Utsunomiya; Hiroji Iwata; Yoshiko Itoh; Johbu Itoh; Reiji Kannagi; Mamoru Kyogashima
Journal:  Glycoconj J       Date:  2010-11-03       Impact factor: 2.916

3.  Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics.

Authors:  Rie Horii; Masaaki Matsuura; Shingo Dan; Masaru Ushijima; Natsue Uehiro; Akiko Ogiya; Naoko Honma; Yoshinori Ito; Takuji Iwase; Takao Yamori; Futoshi Akiyama
Journal:  Int J Clin Oncol       Date:  2014-10-15       Impact factor: 3.402

4.  Immunohistochemical study of metaplastic carcinoma and central acellular carcinoma of the breast: central acellular carcinoma is related to metaplastic carcinoma.

Authors:  Rin Yamaguchi; Maki Tanaka; Keiko Kondo; Toshiro Yokoyama; Ichiro Maeda; Shin-Ichi Tsuchiya; Miki Yamaguchi; Ryuji Takahashi; Yutaka Ogata; Hideyuki Abe; Jun Akiba; Osamu Nakashima; Masayoshi Kage; Hirohisa Yano
Journal:  Med Mol Morphol       Date:  2012-03-20       Impact factor: 2.309

5.  High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy.

Authors:  Tomo Osako; Rie Horii; Masaaki Matsuura; Kaoru Domoto; Yoshimi Ide; Yumi Miyagi; Shunji Takahashi; Yoshinori Ito; Takuji Iwase; Futoshi Akiyama
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-09       Impact factor: 4.553

6.  Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer.

Authors:  Haruko Hiraike; Osamu Wada-Hiraike; Shunsuke Nakagawa; Shigehira Saji; Daichi Maeda; Yuichiro Miyamoto; Kenbun Sone; Michihiro Tanikawa; Katsutoshi Oda; Keiichi Nakagawa; Tetsu Yano; Masashi Fukayama; Yuji Taketani
Journal:  Exp Ther Med       Date:  2011-08-12       Impact factor: 2.447

7.  Genomic heterogeneity of breast tumor pathogenesis.

Authors:  Rachel E Ellsworth; Jeffrey A Hooke; Craig D Shriver; Darrell L Ellsworth
Journal:  Clin Med Oncol       Date:  2009-07-29

Review 8.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

9.  Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.

Authors:  Tomo Osako; Rie Horii; Masaaki Matsuura; Akiko Ogiya; Kaoru Domoto; Yumi Miyagi; Shunji Takahashi; Yoshinori Ito; Takuji Iwase; Futoshi Akiyama
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-14       Impact factor: 4.553

10.  New criteria to predict tumor recurrence in invasive ductal carcinoma of the breast.

Authors:  Tadahiro Nozoe; Emiko Mori; Tomohiro Iguchi; Takahiro Ezaki
Journal:  Int Surg       Date:  2013 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.